A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

Phase shift analysis remains a cornerstone of modern scattering theory, underpinning our understanding of how particles interact under various potential fields. By examining the phase differences ...

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; NA, not applicable; NGS, next-generation sequencing; PCR, polymerase chain reaction. Fig 1. Kaplan-Meier estimates of (A) ...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: ...

Correlative Science in the Cooperative Group System: Re-Engineering for Success Clinical trials frequently include multiple end points that mature at different times. The initial report, typically ...

IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of ...

An open-label non–HLA-A*02 cohort showed a 0.7% annualized recurrence rate after primary immunization with GLSI-100, measured over an average 1.2 patient-years of exposure. Historical comparison to ...

Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...